Citations

Showing 10 of 108162 citations.

Epidemiology and Natural History of Inclusion Body Myositis
Shelly, Shahar , Mielke, Michelle M. , Mandrekar, Jay , Milone, Margherita , Ernste, Floranne C. , Naddaf, Elie , Liewluck, Teerin , Liewluck, T , Mielke, Michelle M , Naddaf, Elie , Shahar, Shelly

Mayo Clinic

Neurology | April 21, 2021 | Volume: 96 | Issue: 21 | Pages: No page available

10.1212/wnl.0000000000012004 | PMID 33879596 Get It

In Reply
Bradford, Leslie , Glaser, Gretchen

Mayo Clinic

Obstetrics & Gynecology | April 21, 2021 | Volume: 137 | Issue: 5 | Pages: 959-959

10.1097/aog.0000000000004372 | PMID 33878052 Get It

“Who Doesn’t Like Receiving Good News?” Perspectives of Individuals Who Received Genomic Screening Results by Mail
Beck, Annika T., Sutton, Erica J., Chow, Carolyn , Curtis, Susan , Sharp, Richard R. , Chow, Carolyn P Y, Curtis, Susan H , Sharp, Richard R , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | April 21, 2021 | Volume: 11 | Issue: 5 | Pages: 322

10.3390/jpm11050322 | PMID 33919001 Get It

As genomic sequencing expands to screen larger numbers of individuals, offering genetic counseling to everyone may not be possible. One approach to managing this limitation is for a genetic counselor to communicate clinically actionable results in person or by telephone, but report other results by mail. We employed this approach in a large genomic implementation study. In this paper, we describe participants’ experiences receiving genomic screening results by mail. We conducted 50 semi-structured telephone interviews with individuals who received neutral genomic screening results by mail. Most participants were satisfied receiving neutral results by mail. Participants generally had a good understanding of results; however, a few participants had misunderstandings about their genomic screening results, including mistaken beliefs about their disease risk and the comprehensiveness of the test. No one reported plans to alter health behaviors, defer medical evaluations, or take other actions that might be considered medically problematic. Reporting neutral results by mail is unlikely to cause recipients distress or generate misunderstandings that may result in reduced vigilance in following recommended preventive health strategies. Nonetheless, some individuals may benefit from additional genetic counseling support to help situate their results in the context of personal concerns and illness experiences.
Novel lincRNA Discovery and Tissue-Specific Gene Expression across 30 Normal Human Tissues
Chen, Xianfeng , Sun, Zhifu , Sun, Zhifu

Mayo Clinic

Genes | April 21, 2021 | Volume: 12 | Issue: 5 | Pages: 614

10.3390/genes12050614 | PMID 33919168 Get It

Long non-coding RNAs (lncRNAs) are a large class of gene transcripts that do not code proteins; however, their functions are largely unknown and many new lncRNAs are yet to be discovered. Taking advantage of our previously developed, super-fast, novel lncRNA discovery pipeline, UClncR, and rich resources of GTEx RNA-seq data, we performed systematic novel lincRNA discovery for over 8000 samples across 30 tissue types. We conducted novel detection for each major tissue type first and then consolidated the novel discoveries from all tissue types. These novel lincRNs were profiled and analyzed along with known genes to identify tissue-specific genes in 30 major human tissue types. Thirteen sub-brain regions were also analyzed in a similar manner. Our analysis revealed thousands to tens of thousands of novel lincRNAs for each tissue type. These lincRNAs could define each tissue type’s identity and demonstrated their reliability and tissue-specific expression. Tissue-specific genes were identified for each major tissue type and sub-brain region. The tissue-specific genes clearly defined each respective tissue’s unique function and could be used to expand the interpretation of non-coding SNPs from genome-wide association (GWAS) studies.
Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer
Kutschat, Ana P. , Johnsen, Steven A. , Hamdan, Feda H. , Johnsen, Steven A , Kutschat, Ana Patricia

Mayo Clinic

Cells | April 21, 2021 | Volume: 10 | Issue: 5 | Pages: 966

10.3390/cells10050966 | PMID 33919156 Get It

Pancreatic ductal adenocarcinoma (PDAC) displays a particularly poor prognosis and low survival rate, mainly due to late diagnosis and high incidence of chemotherapy resistance. Genomic aberrations, together with changes in the epigenomic profile, elicit a shift in cellular signaling response and a transcriptional reprograming in pancreatic tumors. This endows them with malignant attributes that enable them to not only overcome chemotherapeutic challenges, but to also attain diverse oncogenic properties. In fact, certain genetic amplifications elicit a rewiring of calcium signaling, which can confer ER stress resistance to tumors while also aberrantly activating known drivers of oncogenic programs such as NFAT. While calcium is a well-known second messenger, the transcriptional programs driven by aberrant calcium signaling remain largely undescribed in pancreatic cancer. In this review, we focus on calcium-dependent signaling and its role in epigenetic programs and transcriptional regulation. We also briefly discuss genetic aberration events, exemplifying how genetic alterations can rewire cellular signaling cascades, including calcium-dependent ones.
Quinacrine-Induced Autophagy in Ovarian Cancer Triggers Cathepsin-L Mediated Lysosomal/Mitochondrial Membrane Permeabilization and Cell Death
Thirusangu, Prabhu , Pathoulas, Christopher L., Ray, Upasana , Xiao, Yinan , Staub, Julie , Jin, Ling , Khurana, Ashwani, Shridhar, Viji

Mayo Clinic

Cancers | April 21, 2021 | Volume: 13 | Issue: 9 | Pages: 2004

10.3390/cancers13092004 | PMID 33919392 Get It

We previously reported that the antimalarial compound quinacrine (QC) induces autophagy in ovarian cancer cells. In the current study, we uncovered that QC significantly upregulates cathepsin L (CTSL) but not cathepsin B and D levels, implicating the specific role of CTSL in promoting QC-induced autophagic flux and apoptotic cell death in OC cells. Using a Magic Red® cathepsin L activity assay and LysoTracker red, we discerned that QC-induced CTSL activation promotes lysosomal membrane permeability (LMP) resulting in the release of active CTSL into the cytosol to promote apoptotic cell death. We found that QC-induced LMP and CTSL activation promotes Bid cleavage, mitochondrial outer membrane permeabilization (MOMP), and mitochondrial cytochrome-c release. Genetic (shRNA) and pharmacological (Z-FY(tBU)-DMK) inhibition of CTSL markedly reduces QC-induced autophagy, LMP, MOMP, apoptosis, and cell death; whereas induced overexpression of CTSL in ovarian cancer cell lines has an opposite effect. Using recombinant CTSL, we identified p62/SQSTM1 as a novel substrate of CTSL, suggesting that CTSL promotes QC-induced autophagic flux. CTSL activation is specific to QC-induced autophagy since no CTSL activation is seen in ATG5 knockout cells or with the anti-malarial autophagy-inhibiting drug chloroquine. Importantly, we showed that upregulation of CTSL in QC-treated HeyA8MDR xenografts corresponds with attenuation of p62, upregulation of LC3BII, cytochrome-c, tBid, cleaved PARP, and caspase3. Taken together, the data suggest that QC-induced autophagy and CTSL upregulation promote a positive feedback loop leading to excessive autophagic flux, LMP, and MOMP to promote QC-induced cell death in ovarian cancer cells.
Ischemic Mitral Regurgitation: A Multifaceted Syndrome with Evolving Therapies
Vinciguerra, Mattia , Grigioni, Francesco , Romiti, Silvia , Benfari, Giovanni , Rose, David , Spadaccio, Cristiano , Bellis, Antonio De, Greco, Ernesto , Greco, Ernesto , Benfari, Giovanni , Rose, David , Cimino, Sara , Grigioni, Francesco

Mayo Clinic

Biomedicines | April 21, 2021 | Volume: 9 | Issue: 5 | Pages: 447

10.3390/biomedicines9050447 | PMID 33919263 Get It

Dysfunction of the left ventricle (LV) with impaired contractility following chronic ischemia or acute myocardial infarction (AMI) is the main cause of ischemic mitral regurgitation (IMR), leading to moderate and moderate-to-severe mitral regurgitation (MR). The site of AMI exerts a specific influence determining different patterns of adverse LV remodeling. In general, inferior-posterior AMI is more frequently associated with regional structural changes than the anterolateral one, which is associated with global adverse LV remodeling, ultimately leading to different phenotypes of IMR. In this narrative review, starting from the aforementioned categorization, we proceed to describe current knowledge regarding surgical approaches in the management of IMR.
Reply: Telemedicine in Transgender Care: A Twenty-First–Century Beckoning
Rajesh, Aashish , Vyas, Krishna S. , Asaad, Malke , Morrison, Shane D.

Mayo Clinic

Plastic & Reconstructive Surgery | April 21, 2021 | Volume: 147 | Issue: 5 | Pages: 899e-900e

10.1097/prs.0000000000007846 | PMID 33878084 Get It

Reply: Muscle Flap Transposition for the Management of Intrathoracic Fistulas
Shen, K. Robert , Moran, Steven L.

Mayo Clinic

Plastic & Reconstructive Surgery | April 21, 2021 | Volume: 147 | Issue: 5 | Pages: 896e-897e

10.1097/prs.0000000000007835 | PMID 33878061 Get It

National trends in prescription drug expenditures and projections for 2021
Tichy, Eric M. , Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Cuéllar, Sandra , Clark, John Spencer , Wiest, Michelle D., Matusiak, Linda M., Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 21, 2021 | Volume: 78 | Issue: 14 | Pages: 1294-1308

10.1093/ajhp/zxab160 | PMID 33880494 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.